ScholarIQanswers from OpenAlex & ORCID
Baek‐Yeol Ryoo
ResearcherPublications, citations & collaboration network
Baek‐Yeol Ryoo is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Baek‐Yeol Ryoo have?
ScholarIQindexed works
Baek‐Yeol Ryoo has 497 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Baek‐Yeol Ryoo have?
ScholarIQcitation count
Baek‐Yeol Ryoo has 17,902 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Baek‐Yeol Ryoo?
ScholarIQh-index
Baek‐Yeol Ryoo has an h-index of 65 in OpenAlex.
What is the i10-index of Baek‐Yeol Ryoo?
ScholarIQi10-index
Baek‐Yeol Ryoo has an i10-index of 251 in OpenAlex.
What is the ORCID of Baek‐Yeol Ryoo?
ScholarIQorcid
The ORCID for Baek‐Yeol Ryoo is on the source record.
What is the OpenAlex record for Baek‐Yeol Ryoo?
ScholarIQopenalex
The OpenAlex for Baek‐Yeol Ryoo is on the source record.
What are the most-cited papers on Baek‐Yeol Ryoo?
ScholarIQmost cited works
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee, Y-J. Bang, Johanna C. Bendell, Yee Chao, J-S Chen, Hyun Cheol Chung, S. Lindsey Davis, Atul Dev, Edward Gane, Ben George, Aiwu Ruth He, Howard S. Höchster, C-H Hsu, Masafumi Ikeda, Jes Chauviere Lee, M. Lee, Amit Mahipal, Gulam A. Manji, Manabu Morimoto, Kazushi Numata, Michael J. Pishvaian, Shukui Qin, David P. Ryan, B-Y Ryoo, Naoki Sasahira, Stacey Stein, John H. Strickler, N. C. Tebbutt
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone I. Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer J. Knox, Janine M. Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis J. Villanueva-Rivera, Patricio Yañez Weber, Marcelo Garrido, Gonzalo Pizarro, Nicolás Yáñez, Ruocai Xu, Shuangyan Ou, Zhenggang Ren, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Shukui Qin, Juxiang Xiao, Weijia Fang, Xin Wang, Yuxian Bai, Xiaoming Chen, Dong Yan, Hong Zhao, Jieer Ying, Carlos Bonilla, Olga Urrego, Ángela R. Zambrano, Mauricio Lema, Juan Carlos Restrepo, Andrés F. Cardona, Sandra Franco Millan, Madiedo Oscar, Víctor Ramos, Philippe Merle, Samuel Lesourd, Julien Edeline, Jean–Pierre Bronowicki, Marc Bourlière, Stéphane Cattan, Mohamed Bouattour, Laurent Mineur, Hélène Regnault, Barbara Dauvois, Kornelius Schulze, Gunnar Folprecht, Andreas Geier, Oliver Waidmann, Fabian Finkelmeier, Marino Venerito, Marie‐Luise Berres, Thomas Berg, Christian M. Lange, Hartmut Schmidt, Dirk Waldschmidt, Michael Bitzer, Ray McDermott, Austin G. Duffy, Gianluca Masi, Vittorina Zagonel, Giuseppe Tonini, Fabio Piscaglia, Stefania Gori, Mimma Rizzo, Elisa Biscaldi
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, George Pentheroudakis, Si-bei Qin, G.S. Bhattacharyya, Masafumi Ikeda, Ho Yeong Lim, Gwo Fuang Ho, Su Pin Choo, Zhenggang Ren, Hemant Malhotra, Makoto Ueno, Baek‐Yeol Ryoo, Tina Kiang, David Tai, Arndt Vogel, Andrés Cervantes, Sheng‐Nan Lu, Chung‐Jen Yen, Yi‐Hsiang Huang, San‐Chi Chen, Chiun Hsu, Ying‐Chun Shen, Josep Tabernero, Yun Yen, Chih‐Hung Hsu, Takayuki Yoshino, J.-Y. Douillard
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
Jin Kyung Rho, Yun Jung Choi, Jin Kyung Lee, Jin Kyung Lee, Baek‐Yeol Ryoo, Im Il Na, Sung Hyun Yang, Cheol Hyeon Kim, Jae Cheol Lee, Jae Cheol Lee